Company intelligence / Profile preview
LISCure Biosciences
Seongnam-si, Gyeonggi-do / Seongnam-si / Bundang-gu, South Korealiscure.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
LISCure is advancing a pipeline of microbiome-based drugs with its lead candidate LB-P8 in Phase 2 trials for primary sclerosing cholangitis. Other programs target autoimmune diseases, neurodegenerative disorders, and oncology. The company leverages its proprietary platform to develop both injectable bacteria-mediated cancer immunotherapies and oral microbiome therapeutics. No pivotal clinical results have been published yet.
- Therapeutic areas
- GastroenterologyOncologyImmunologyNeurology
- Modalities
- Live biotherapeutic products (LBPs)Biological productsMicrobiota-based therapeutics
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on LISCure Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LISCure Biosciences.